MedWatch

Biotech stocks ready for more Covid-19 results in first quarter

Potential approval of an Alzheimer’s medicine, new gene therapy data and more late-stage clinical trial results for Covid-19 vaccines will keep momentum up for biotech stocks in the next three months.

Photo: Issei Kato/REUTERS / X90003

The benchmark Nasdaq Biotech Index has climbed 26% this year, compared with a 15% gain in the S&P 500 Index, pointing to no let-up in market-moving drug trial data even during the pandemic.

While the index hit a bump this week amid worries of delays in distribution of the two U.S.-approved inoculations, investors are on the lookout as a second group of vaccine developers race to test shots, including those from Novavax, Johnson & Johnson and partners Glaxosmithkline and Sanofi.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Latest news

See all jobs